Hikma Pharmaceuticals Statistics
Share Statistics
Hikma Pharmaceuticals has 220.43M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 220.43M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 14.87 and the forward
PE ratio is null.
Hikma Pharmaceuticals's PEG ratio is
0.17.
| PE Ratio | 14.87 |
| Forward PE | n/a |
| PS Ratio | 1.71 |
| Forward PS | n/a |
| PB Ratio | 2.31 |
| P/FCF Ratio | 13.38 |
| PEG Ratio | 0.17 |
Financial Ratio HistoryEnterprise Valuation
Hikma Pharmaceuticals has an Enterprise Value (EV) of 6.46B.
| EV / Sales | 2.06 |
| EV / EBITDA | 8.2 |
| EV / EBIT | 11.45 |
| EV / FCF | 16.18 |
Financial Position
The company has a current ratio of 1.14,
with a Debt / Equity ratio of 0.57.
| Current Ratio | 1.14 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 1.66 |
| Debt / FCF | 3.27 |
| Interest Coverage | 8.16 |
Financial Efficiency
Return on Equity is 15.54% and Return on Invested Capital is 12.79%.
| Return on Equity | 15.54% |
| Return on Assets | 6.99% |
| Return on Invested Capital | 12.79% |
| Revenue Per Employee | $329,157.89 |
| Profits Per Employee | $37,789.47 |
| Employee Count | 9,500 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.74 |
Taxes
| Income Tax | 93M |
| Effective Tax Rate | 20.44% |
Stock Price Statistics
The stock price has increased by 17.33% in the
last 52 weeks. The beta is 0.69, so Hikma Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.69 |
| 52-Week Price Change | 17.33% |
| 50-Day Moving Average | 26.66 |
| 200-Day Moving Average | 25.46 |
| Relative Strength Index (RSI) | 37.05 |
| Average Volume (20 Days) | 240 |
Income Statement
In the last 12 months, Hikma Pharmaceuticals had revenue of 3.13B
and earned 359M
in profits. Earnings per share was 1.61.
| Revenue | 3.13B |
| Gross Profit | 1.42B |
| Operating Income | 612M |
| Net Income | 359M |
| EBITDA | 787M |
| EBIT | 608M |
| Earnings Per Share (EPS) | 1.61 |
Full Income StatementBalance Sheet
The company has 188M in cash and 1.31B in
debt, giving a net cash position of -1.12B.
| Cash & Cash Equivalents | 188M |
| Total Debt | 1.31B |
| Net Cash | -1.12B |
| Retained Earnings | 2.36B |
| Total Assets | 5.13B |
| Working Capital | 285M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 564M
and capital expenditures -165M, giving a free cash flow of 399M.
| Operating Cash Flow | 564M |
| Capital Expenditures | -165M |
| Free Cash Flow | 399M |
| FCF Per Share | 1.8 |
Full Cash Flow StatementMargins
Gross margin is 45.25%, with operating and profit margins of 19.57% and 11.48%.
| Gross Margin | 45.25% |
| Operating Margin | 19.57% |
| Pretax Margin | 14.55% |
| Profit Margin | 11.48% |
| EBITDA Margin | 25.17% |
| EBIT Margin | 19.57% |
| FCF Margin | 12.76% |
